Trial Search Results
The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection
To determine the safety of thymosin alpha 1 given twice weekly in a regimen of daily oral zidovudine (AZT) and biweekly polyethylene glycolated interleukin-2 (PEG IL-2). To determine the effect of thymosin alpha 1 and PEG IL-2 in combination with AZT on immunologic and pharmacokinetic markers.
AIDS is characterized by diminished T helper cell number and function. Thymosin alpha 1 appears to both increase IL-2 receptors on lymphocytes in vitro and enhance lymphocyte maturation in vivo; thus, the drug may further enhance the CD4 T cell levels in patients receiving AZT and PEG IL-2.
Stanford is currently not accepting patients for this trial.
National Institute of Allergy and Infectious Diseases (NIAID)
- Drug: Thymalfasin
- Drug: Interleukin-2, Polyethylene Glycolated
- Drug: Zidovudine
- Prophylactic pentamidine for Pneumocystis carinii.
Patients must have:
- HIV seropositivity.
- CD4 count > 50 and < 200 cells/mm3.
- No active opportunistic infections.
Patients with the following symptoms or conditions are excluded:
- Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of
the cervix, or Kaposi's sarcoma.
- Significant cardiac disease or CNS lesions or other neurologic abnormalities.
- Score of > 0.5 on ACTG AIDS Dementia Complex staging.
- Major organ allograft.
- Intolerance to AZT at 500 mg/day.
- Antihypertensive medication other than diuretics.
- Chemotherapy, hormonal therapy, or other immunotherapy.
- Other investigational drugs, agents, or devices.
- Non-topical steroids.
- Radiation therapy.
- Known anti-HIV medication (other than AZT) or known immunomodulators (e.g., systemic
steroids, interferons, interleukins) or other chemotherapy within 30 days prior to
- Transfusion within 4 weeks prior to study entry.
- Radiation within 30 days prior to study entry.
Active substance abuse.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study